SHTDY (Sinopharm Group Co) Interest Expense : $-376 Mil (TTM As of Jun. 2024)

View and export this data going back to 2012. Start your Free Trial

What is Sinopharm Group Co Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Sinopharm Group Co's interest expense for the six months ended in Jun. 2024 was $ -188 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jun. 2024 was $-376 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Sinopharm Group Co's Operating Income for the six months ended in Jun. 2024 was $ 1,157 Mil. Sinopharm Group Co's Interest Expense for the six months ended in Jun. 2024 was $ -188 Mil. Sinopharm Group Co's Interest Coverage for the quarter that ended in Jun. 2024 was 6.17. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Sinopharm Group Co Interest Expense Historical Data

The historical data trend for Sinopharm Group Co's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinopharm Group Co Interest Expense Chart

Sinopharm Group Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Interest Expense

Get a 7-Day Free Trial

-523.72

-589.84

-504.95

-414.08

-375.52

Sinopharm Group Co Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Interest Expense	Get a 7-Day Free Trial															-246.19	-231.96	-181.43	-187.52	-188.67

Sinopharm Group Co Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-376 Mil.

Sinopharm Group Co (OTCPK:SHTDY) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Sinopharm Group Co's Interest Expense for the six months ended in Jun. 2024 was $-188 Mil. Its Operating Income for the six months ended in Jun. 2024 was $1,157 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Jun. 2024 was $2,702 Mil.

Sinopharm Group Co's Interest Coverage for the quarter that ended in Jun. 2024 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Jun. 2024 )	/	Interest Expense (Q: Jun. 2024 )
	=	-1	*	1156.793	/	-187.523
	=	6.17

The higher the ratio, the stronger the company's financial strength is.

Sinopharm Group Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Sinopharm Group Co Ltd (OTCPK:SHTDY) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

SHTDF:USA 01099:Hong Kong X2S:Germany

Address

No. 385, East Longhua Road, Sinopharm Group Building, Huangpu District, Shanghai, CHN, 200023

Website

http://www.sinopharmgroup.com.cn

Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2023. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.

Sinopharm Group Co Headlines

From GuruFocus

Matthews China Fund Comments on Sinopharm Group

By Vera Yuan Vera Yuan • 10-20-2014

Matthews China Fund Q3 2014 Commentary

By Holly LaFon Holly LaFon • 10-18-2014

Matthews China Fund Comments on Sinopharm

By Holly LaFon Holly LaFon • 05-19-2016

Arnold Van Den Berg Buys Prem Watsa's Fairfax India, 3 Other Stocks in 3rd Quarter

By Holly LaFon Holly LaFon • 10-31-2017

Matthews China Fund 1st Quarter Commentary

By Holly LaFon Holly LaFon • 05-19-2016

Sinopharm Group Co Ltd's Dividend Analysis

By GuruFocus Research • 06-17-2024

Matthews China Fund Comments on Sinopharm

By Sydnee Gatewood Sydnee Gatewood • 01-25-2021

Matthews China Fund Comments on Sinopharm

By Sydnee Gatewood Sydnee Gatewood • 07-30-2020